Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibiotic
    (2)
  • Autophagy
    (1)
  • Parasite
    (2)
  • SARS-CoV
    (2)
  • STAT
    (2)
  • Others
    (5)
Filter
Search Result
Results for "niclosamide" in TargetMol Product Catalog
  • Inhibitor Products
    9
    TargetMol | Activity
Niclosamide monohydrate
T2306873360-56-2
Niclosamide Monohydrate is used for the treatment of most tapeworm infections by inhibiting DNA replication.
  • $1,520
6-8 weeks
Size
QTY
Niclosamide
T071150-65-7
Niclosamide (Niclocide)(BAY2353) is used to treat most tapeworm infections by inhibiting DNA replication.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Niclosamide sodium
T7251940321-86-6
Niclosamide sodium (BAY2353), an orally active antihelminthic agent employed in parasitic infection research, serves as a potent STAT3 inhibitor, demonstrating an IC50 of 0.25 μM in HeLa cells. Additionally, this compound exhibits significant biological activities against cancer and effectively inhibits DNA replication in Vero E6 cells.
  • $1,520
6-8 weeks
Size
QTY
Niclosamide olamine
T0711L1420-04-8
Niclosamide olamine (Niclosamide Ethanolamine salt) is an Repellent, Insect Attractant and Chemosterilant.
  • $39
In Stock
Size
QTY
SARS-CoV-2-IN-14
T6053822203-98-1
SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.
  • $39
In Stock
Size
QTY
SARS-CoV-2-IN-13
T6091956961-10-5
SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1].
  • $51
In Stock
Size
QTY
JMX0312
T69250439144-75-9
JMX0312 is a salicylamide derivative used as a potent inhibitor of HAdV infection. JMX0312 showed significantly improved anti-HAdV activities with nanomolar to submicromolar IC50 values and high selectivity indexes (SI > 100), indicating better safety windows, compared to those of the lead compound niclosamide.
  • $1,520
6-8 weeks
Size
QTY
TFM
T3763288-30-2
TFM is a piscicide.1It is toxic to sea lamprey (P. marinus) with LC50values ranging from 1.97 to 2.11 and 2.05 to 2.21 mg/L for sac and swim-up fry, respectively, 1.6 to 2.45 mg/L for juveniles, and 1.6 to 1.63 mg/L for adults. It is also toxic to juvenile lake sturgeon (A. fulvescens) less than 100 mm in size but not to a variety of other fish species. TFM (50 μM) uncouples oxidative phosphorylation by 22 and 28% in isolated sea lamprey and rainbow trout (O. mykiss) liver, respectively.2Formulations containing TFM have been used as lampricides in the control of larval sea lamprey populations. 1.Boogaard, M.A., Bills, T.D., and Johnson, D.A.Acute toxicity of TFM and a TFM/niclosamide mixture to selected species of fish, including lake sturgeon (Acipenser fulvescens) and mudpuppies (Necturus maculosus), in laboratory and field exposuresJ. Great Lakes Res.29(Suppl 1)529-541(2003) 2.Birceanu, O., McClelland, G.B., Wang, Y.S., et al.The lampricide 3-trifluoromethyl-4-nitrophenol (TFM) uncouples mitochondrial oxidative phosphorylation in both sea lamprey (Petromyzon marinus) and TFM-tolerant rainbow trout (Oncorhynchus mykiss)Comp. Biochem. Physiol. C. Toxicol. Pharmacol.153(3)342-349(2011)
  • $78
35 days
Size
QTY
SARS-CoV-2-IN-15
T608181580-42-3
SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue that contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. It improves bioavailability and half-life when administered orally. SARS-CoV-2-IN-15 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.49 μM [1].
  • $1,520
6-8 weeks
Size
QTY